ORCA-010 Clinical Study in Prostate Cancer Selected for a Late Breaking Abstract Presentation at the ASGCT conference 

[Amsterdam, The Netherlands – April 2024] – ORCA Therapeutics BV, a leading biopharmaceutical company specializing in oncolytic immunotherapies, proudly announces the selection of  for a Late Breaking Abstract Presentation at the prestigious American Society for Gene and Cell therapy (ASGCT) conference. The conference is scheduled to take place in Baltimore, USA, from May 7th to May 11th , 2024.

The presentation titled ” Oncolytic adenovirus ORCA-010 induces systemic tumor-specific T cell responses and activation of the tumor microenvironment in prostate cancer: A Phase I/IIa clinical trial” will highlight the safety, anti-tumor effects and interim data on immune modulation induced by ORCA-010. The abstract was selected after peer review by independent experts in the oncology and cell and gene therapy field.  ORCA Therapeutics is honored to have its groundbreaking research recognized by the Scientific Committee. This recognition further validates the importance and novelty of the clinical findings with ORCA-010 in prostate cancer.

The late Breaking Abstract Presentation provides an unique opportunity for ORCA Therapeutics to share results from the ongoing Phase I/IIA clinical trial, demonstrating the extra-ordinary ability of ORCA-010 to not only activate the tumor immune micro-environment, but also to induce systemic anti-tumor immune responses in prostate cancer patients.

ORCA Therapeutics  looks forward to contributing to the dialogue on the development of innovative and transformative therapies for cancer treatment.

For further information and media inquiries, please contact:
Dr. Wenliang Dong, Ph.D. MBA
Email: wen.dong@orca-therapeutics.com
Website: www.orca-therapeutics.com

About ORCA Therapeutics BV: ORCA Therapeutics BV is a clinical stage biopharmaceutical company dedicated to developing oncolytic immunotherapies for cancer treatment. With a focus on innovative gene therapies, ORCA Therapeutics is committed to improving patient outcomes and addressing unmet medical needs. Learn more at www.orca-therapeutics.com